India’s Sun Pharma Estimates Taro Buyout At $21.3 Million
This article was originally published in PharmAsia News
Executive Summary
Sun Pharmaceutical Industries of India now estimates its offer to buy all of Israel's Taro Pharmaceuticals will cost it about $21.3 million. The Indian drug maker has been trying to buy the Israeli firm ever since the companies had a falling out over a merger agreement just over two years ago. Each sued the other and Sun, which already owned 36 percent of Taro, has extended its open offer 10 times. Sun now is awaiting a decision by Israel's Supreme Court over the matter. Sun Chairman Dilip Shanghvi estimated the latest cost of the takeover. (Click here for more
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.